A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

November 21, 2014
There Is a Chance to Build Upon One HIV Vaccine’s Moderate Success
New research suggests that retooling of vaccine found moderately successful could yield efficacy high enough to prevent most HIV infections.
November 20, 2014
Harvoni Cures Almost All People With Hep C Coinfected With HIV
Twelve weeks of Gilead Sciences’ newly approved Harvoni cured nearly all people with genotype 1 of hepatitis C who were coinfected with HIV in a recent trial.
Mother-to-Child HIV Transmission Is Best Prevented With 3 Drugs
Taking a triple-antiretroviral regimen is best for preventing mother-to-child transmission during pregnancy, rather than taking one drug during pregnancy, another during labor and two more after giving birth.
November 19, 2014
U.S. HIV 'Treatment Cascade' Stats Are Dismal Among Western Nations
Compared with other high-income Western nations, the United States HIV treatment cascade figures are remarkably bad.
November 18, 2014
Racial Disparities in the Gay Male HIV Epidemic Appear Entrenched
Black men who have sex with men will likely continue to have disproportionately high HIV rates for decades.
November 17, 2014
High Post-Liver Transplant Survival Rates for People With HIV
HIV-positive people who have liver transplants because of liver cancer have high survival rates.
Age-Related Diseases Not Occurring Earlier for People With HIV
While HIV-positive people do experience higher rates of age-related diseases, they don't experience them at younger ages than HIV-negative people.
November 14, 2014
New Potential HIV Treatment Target Is Discovered
Researchers have identified a new protein that participates in HIV’s replication process, opening the door for development of a potential therapy targeting the protein.
November 13, 2014
Vaginal Ring May Protect Against HIV, Herpes, HPV and Pregnancy
A multipurpose vaginal ring has shown promise in protecting against HIV, genital herpes, HPV and pregnancy in a primate study.
November 12, 2014
Excellent Results for 12 and 18 Weeks of Merck’s Dual Hep C Regimen
Twelve or 18 weeks of Merck’s grazoprevir/elbasvir, with or without ribavirin, cured 91 to 100 percent of hard-to-treat people with genotype 1 of hepatitis C.
November 11, 2014
Viread Gel Linked to Lowered Risk of Herpes Among Women
Women who regularly used a Viread (tenofovir)–based vaginal gel had a 46 percent reduced risk of acquiring herpes, according to a secondary analysis of the VOICE trial.
November 10, 2014
Hep C Cure Lowers Risk of Death, Liver Cancer and Transplants
Achieving a cure for hepatitis C through interferon-based treatment reduces the risk of death, liver cancer and needing a liver transplant.
High Success For Harvoni Treating Coinfected Genotype 1
Harvoni (ledipasvir/sofosbuvir) is proving highly successful at treating hepatitis C among people coinfected with HIV and genotype 1 of hep C in an ongoing small trial.
Researchers See New Avenue For HIV Cure: Endogenization
Scientists believe they have identified the means by which two men were “spontaneously cured" of HIV, and that this insight may carve a new cure pathway.
November 07, 2014
Latest Data on PrEP, Though Patchy, Indicates Rising Use Among Men
The use of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) is on the rise in the United States, in particular among men.
November 06, 2014
FDA Approves Olysio-Sovaldi Hep C Combo
The FDA has granted approval of Olysio (simeprevir) and Sovaldi (sofosbuvir) to be used in combination to treat genotype 1 of hepatitis C.
FDA Reviews First Single-Tablet HIV Regimen Containing TAF
The pill has the same antiretrovirals as Stribild, but with a new version of tenofovir.
November 04, 2014
Gays May See Monogamy as Barrier to HIV, Even Without Testing
Research suggests that young gay men’s understanding of what constitutes “safer sex” factors in condoms, testing and monogamy.
November 03, 2014
More PrEP Needed To Prevent HIV Via Vaginal Than Anal Sex
Greater dosing of Viread (tenofovir) or Truvada (tenofovir/emtricitabine) as PrEP is needed to reach effective levels in vaginal and cervical tissue than in recal tissue.
Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?

November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006
October 2005

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.